Breaking Down Taysha Gene Therapies: 16 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
16 analysts have shared their evaluations of Taysha Gene Therapies (NASDAQ:TSHA) over the past three months, showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target has increased by 46.11% to $6.94. Analysts have maintained or raised their ratings, with the highest price target set at $9.00. Despite financial challenges, including a -27.52% revenue decline and high debt-to-equity ratio, analysts remain optimistic about the company's future.
May 28, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown a mix of bullish and somewhat bullish perspectives on Taysha Gene Therapies, with the average 12-month price target increasing by 46.11% to $6.94. Despite financial challenges, the highest price target is set at $9.00.
The increase in the average price target by 46.11% and the highest target of $9.00 indicate strong analyst confidence in the company's future performance. Despite financial challenges, the consistent 'Buy' and 'Overweight' ratings suggest a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100